Biocad
Biosimilar developer, Russia. 3 development products across 3 molecules: infliximab, rituximab, trastuzumab.
First approval in the Atlas: Jul 2017, Biocad India (INN only), rituximab (CDSCO)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved3
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Infliximab | Biocad infliximab BCD-055 | · | · | · | · | Dec 2019 | · |
| Rituximab | Biocad rituximab BCD-020 | · | · | · | · | Jul 2017 | · |
| Trastuzumab | Biocad trastuzumab BCD-022 | · | · | · | · | Apr 2018 | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- CDSCOJul 2017Biocad India (INN only), rituximab
- CDSCOApr 2018Biocad India (INN only), trastuzumab
- CDSCODec 2019Biocad India (INN only), infliximab
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.